Steven Erly

Mr. Steven Erly


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2020 in Viruses
Verified
Journal Article
Open access
PDF file
SESteven Erly
Steven Erly
JHJoshua T. Herbeck
Joshua T. Herbeck
RKRoxanne P. Kerani
Roxanne P. Kerani
JRJennifer Reuer
Jennifer Reuer
Molecular cluster detection can be used to interrupt HIV transmission but is dependent on identifying clusters where transmission is likely. We characterized molecular cluster detection in Washington State, evaluated the current cluster investigation criteria, and developed a criterion using machine learning. The population living with HIV (PLWH) in Washington State, those with an analyzable genotype sequences, and those in clusters were described across demographic characteristics from 2015 to2018. The relationship between 3- and 12-month cluster growth and demographic, clinical, and temporal predictors were described, and a random forest model was fit using data from 2016 to 2017. The ability of this model to identify clusters with future transmission was compared to Centers for Disease Control and Prevention (CDC) and the Washington state criteria in 2018. The population with a genotype was similar to all PLWH, but people in a cluster were disproportionately white, male, and men who have sex with men. The clusters selected for investigation by the random forest model grew on average 2.3 cases (95% CI 1.1–1.4) in 3 months, which was not significantly larger than the CDC criteria (2.0 cases, 95% CI 0.5–3.4). Disparities in the cases analyzed suggest that molecular cluster detection may not benefit all populations. Jurisdictions should use auxiliary data sources for prediction or continue using established investigation criteria.

18 November 2020 in Journal of Immigrant and Minority Health
Verified
Journal Article
Closed access
PDF file
SESteven Erly
Steven Erly
DRD. Allen Roberts
D. Allen Roberts
RKRoxanne Kerani
Roxanne Kerani
HKH. Nina Kim
H. Nina Kim
RHRobert Harrington
Robert Harrington
RPRena Patel
Rena Patel

4 May 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SESteven Erly
Steven Erly
CKChristine M. Khosropour
Christine M. Khosropour
AHAnjum Hajat
Anjum Hajat
MSMonisha Sharma
Monisha Sharma
JRJennifer R. Reuer
Jennifer R. Reuer
JDJulia C. Dombrowski
Julia C. Dombrowski
AIDS Drug Assistance Programs (ADAPs) are state-administered programs that pay for medical care for people living with HIV in the US. Maintaining enrollment in the programs is challenging, and a large proportion of clients in Washington state (WA) fail to recertify and are disenrolled. In this study we sought to quantify the impact of disenrollment from ADAPs on viral suppression. We conducted a retrospective cohort study of the 5238 clients in WA ADAP from 2017 to 2019 and estimated the risk difference (RD) of viral suppression before and after disenrollment. We performed a quantitative bias analysis (QBA) to assess the effect of unmeasured confounders, as the factors that contribute to disenrollment and medication discontinuation may overlap. Of the 1336 ADAP clients who disenrolled ≥1 time, 83% were virally suppressed before disenrollment versus 69% after (RD 12%, 95%CI 9–15%). The RD was highest among clients with dual Medicaid-Medicare insurance (RD 22%, 95%CI 9–35%) and lowest among privately insured individuals (RD 8%, 95%CI 5–12%). The results of the QBA suggest that unmeasured confounders do not negate the overall RD. The ADAP recertification procedures negatively impact the care of clients who struggle to stay in the program; alternative procedures may reduce this impact.

14 June 2024 in American Journal of Epidemiology
Verified
Journal Article
Closed access
PDF file
SESteven Erly
Steven Erly
CMClaire M Mocha
Claire M Mocha
RARachel M Amiya
Rachel M Amiya
SGSara N Glick
Sara N Glick
Rural environments in the United States present challenges to wellness, but there is a lack of tools with which to categorize rurality at the subcounty level. The most common tool, the Food and Drug Administration’s 2010 Rural–Urban Commuting Area (RUCA) codes, uses data that are over a decade old and cannot accommodate regional differences in rurality. The purpose of this study was to develop a census-tract classification system of rurality and demonstrate its use in describing HIV outcomes. We transformed census-tract measures (population density, natural resource workforce, walkability index, household type, and air quality) into local scales of rurality using factor analysis. We surveyed public health practitioners to determine cutpoints and compared the resulting categorization with RUCA codes. We characterized the incidence of HIV in Washington State according to rurality category. Our classification system categorized 25% of census tracts as rural, 19% as periurban, and 56% as urban. Our survey yielded cutoffs that were more conservative in categorizing urban areas than RUCA codes. The rate of HIV diagnosis was substantially higher in urban areas. Our rural–urban classification system offers an alternative to RUCA codes that is more responsive to regional differences.

1 June 2024 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
SESteven Erly
Steven Erly
TMTim W. Menza
Tim W. Menza
LGLauren Granillo
Lauren Granillo
MNMichael Navejas
Michael Navejas
CUChi-Chi N. Udeagu
Chi-Chi N. Udeagu
SBSusan Buskin
Susan Buskin
Background: The COVID-19 pandemic disrupted global economic and healthcare systems. People living with HIV (PLWH) represent a marginalized and stigmatized population who may have been particularly impacted. The purpose of this analysis was to describe the impact of the COVID-19 pandemic on PLWH in the United States. Setting: United States. Methods: We analyzed surveys of behavioral and clinical characteristics of PLWH residing in 5 states that participated in the Medical Monitoring Project between 2020 and 2022. We described the impact of COVID-19 illness, testing, and diagnoses; receipt of medical care; social service access; employment; and preventive measures by project site and demographic characteristics. Results: Unweighted data from 1715 PLWH were analyzed. A high proportion of PLWH had medical care disrupted by the pandemic; 31% of PLWH missed medical appointments, 26% missed routine laboratory test results, and 7% missed antiretroviral therapy doses. In total, 30% of PLWH reported losing wages and 19% reported difficulty in accessing social services. Overall, 88% reported receiving at least 1 dose of COVID-19 vaccine, but vaccine uptake was low among younger, Black, and Hispanic or Latina/o/x PLWH. Conclusions: This descriptive analysis reinforces previous findings that show that COVID-19 negatively impacted PLWH and their ability to obtain medical care. Additional efforts will be critical to ameliorating the longer-term impacts of COVID-19 on the health of PLWH and supporting PLWH through future pandemics and healthcare system disruptions.

19 April 2022 in Journal of Women's Health
Verified
Journal Article
Closed access
SESteven Erly
Steven Erly
TFTerra R. Forward
Terra R. Forward
ZRZoe H. Rogers
Zoe H. Rogers
SHStephen E. Hawes
Stephen E. Hawes
EMElizabeth Micks
Elizabeth Micks
Objective: Medical contraindications to estrogen limit women's contraceptive options. This study assessed the association between selected medical contraindications to estrogen on contraceptive use and examined whether contraindications serve as a barrier to the prevention of unintended pregnancy. Materials and Methods: We analyzed women aged 18–44 at risk of unintended pregnancy participating in the 2017 Behavioral Risk Factor Surveillance System. Survey questions queried women regarding contraceptive use and contraindications to estrogen use. We assessed the most recently used contraceptive method and compared the odds of women using each category of contraception (no methods, less effective methods, pill/patch/ring, injection, intrauterine device, implant, permanent contraception) between those with and without potential contraindications to estrogen using multinomial logistic regression models. Results: This study included 32,098 women, of whom 16% had one or more potential contraindications to estrogen. There were significant differences in contraceptive choice by potential contraindication status ( p < 0.01). Fifteen percent of women with potential contraindications reported using estrogen-containing methods (pill, patch, or ring) compared with 20% of women with no potential contraindication. Women with potential contraindications to estrogen more frequently used permanent contraception (odds ratio [OR] vs. pill/patch/ring: 1.48 95% confidence interval [CI]: 1.17–1.88) or no contraceptive method (OR vs. pill/patch/ring: 1.37 95% CI: 1.07–1.75) after adjustment for race, age, marital status, and income. Conclusions: Potential medical contraindications to estrogen are associated with permanent contraception and the use of no contraception. These results portray a complicated relationship but could suggest a lack of access to other contraceptive options.